US Stocks Movements | Rani Therapeutics (RANI.US) Soars Over 265% After $1.085 Billion Partnership Agreement with Chugai Pharmaceutical

Stock News

Oct 17

On Friday, Rani Therapeutics (RANI.US) surged over 265%, triggering a trading halt at one point and hitting a new annual high of $1.76. The spike in stock price follows the company’s announcement of a partnership with Chugai Pharmaceutical worth up to $1.085 billion. The agreement includes a $10 million upfront payment, eligibility for up to $75 million in technology transfer and development milestone payments, $100 million in sales milestone payments, and a single-digit royalty. Additionally, Chugai has the option to expand the collaboration to five additional drug targets. Rani Therapeutics specializes in oral delivery technologies for biopharmaceuticals, with its core platform, RaniPill®, dedicated to the development of oral antibodies and treatments for rare diseases. This collaboration focuses on Chugai's rare disease antibody projects to validate the technological application value.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1129293612"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1129293612\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1129293612?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-17 23:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1129293612","market":"hk","top_or_hot":-1,"title":"US Stocks Movements | Rani Therapeutics (RANI.US) Soars Over 265% After $1.085 Billion Partnership Agreement with Chugai Pharmaceutical","media":"Stock News","content":"<p>On Friday, Rani Therapeutics (RANI.US) surged over 265%, triggering a trading halt at one point and hitting a new annual high of $1.76. The spike in stock price follows the company’s announcement of a partnership with Chugai Pharmaceutical worth up to $1.085 billion. The agreement includes a $10 million upfront payment, eligibility for up to $75 million in technology transfer and development milestone payments, $100 million in sales milestone payments, and a single-digit royalty. Additionally, Chugai has the option to expand the collaboration to five additional drug targets. Rani Therapeutics specializes in oral delivery technologies for biopharmaceuticals, with its core platform, RaniPill®, dedicated to the development of oral antibodies and treatments for rare diseases. This collaboration focuses on Chugai's rare disease antibody projects to validate the technological application value.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US Stocks Movements | Rani Therapeutics (RANI.US) Soars Over 265% After $1.085 Billion Partnership Agreement with Chugai Pharmaceutical</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS Stocks Movements | Rani Therapeutics (RANI.US) Soars Over 265% After $1.085 Billion Partnership Agreement with Chugai Pharmaceutical\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-10-17 23:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>On Friday, Rani Therapeutics (RANI.US) surged over 265%, triggering a trading halt at one point and hitting a new annual high of $1.76. The spike in stock price follows the company’s announcement of a partnership with Chugai Pharmaceutical worth up to $1.085 billion. The agreement includes a $10 million upfront payment, eligibility for up to $75 million in technology transfer and development milestone payments, $100 million in sales milestone payments, and a single-digit royalty. Additionally, Chugai has the option to expand the collaboration to five additional drug targets. Rani Therapeutics specializes in oral delivery technologies for biopharmaceuticals, with its core platform, RaniPill®, dedicated to the development of oral antibodies and treatments for rare diseases. This collaboration focuses on Chugai's rare disease antibody projects to validate the technological application value.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1129293612","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1129293612","pubTimestamp":1760715994,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"On Friday, Rani Therapeutics (RANI.US) surged over 265%, triggering a trading halt at one point and hitting a new annual high of $1.76. The spike in stock price follows the company’s announcement of...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","LENZ":"Therapeutics","BK4007":"制药","01477":"欧康维视生物-B","BK4539":"次新股","BK1191":"制药","RANI":"Rani Therapeutics Holdings","BK1574":"生物医药B类股"},"translate_title":"美股动向|Rani Therapeutics(RANI.US)与中外制药达成10.85亿美元合作协议后飙升超265%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01477":1,"LENZ":1,"RANI":1},"content_text":"On Friday, Rani Therapeutics (RANI.US) surged over 265%, triggering a trading halt at one point and hitting a new annual high of $1.76. The spike in stock price follows the company’s announcement of a partnership with Chugai Pharmaceutical worth up to $1.085 billion. The agreement includes a $10 million upfront payment, eligibility for up to $75 million in technology transfer and development milestone payments, $100 million in sales milestone payments, and a single-digit royalty. Additionally, Chugai has the option to expand the collaboration to five additional drug targets. Rani Therapeutics specializes in oral delivery technologies for biopharmaceuticals, with its core platform, RaniPill®, dedicated to the development of oral antibodies and treatments for rare diseases. This collaboration focuses on Chugai's rare disease antibody projects to validate the technological application value.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}